Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 16 AL 30

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease

Cardoso BR, Roberts BR, Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, Hicks RJ, Callahan J, Brodtmann A, Collins S, Macfarlane S, Corcoran NM, Hovens CM, Velakoulis D, O'Brien TJ, Hare DJ, Bush AI.

Neurotherapeutics. 2019 Jan;16(1):192-202. doi: 10.1007/s13311-018-0662-z.

Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?

Zholos AV, Moroz OF, Storozhuk MV.

Curr Mol Pharmacol. 2019;12(1):12-26. doi: 10.2174/1874467211666181012150847.

Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial

Sha SJ, Deutsch GK, Tian L, Richardson K, Coburn M, Gaudioso JL, Marcal T, Solomon E, Boumis A, Bet A, Mennes M, van Oort E, Beckmann CF, Braithwaite SP, Jackson S, Nikolich K, Stephens D, Kerchner GA, Wyss-Coray T.

JAMA Neurol. 2019 Jan 1;76(1):35-40. doi: 10.1001/jamaneurol.2018.3288.

Extending Arms of Insulin Resistance from Diabetes to Alzheimer's Disease: Identification of Potential Therapeutic Targets

Gupta S, Singhal NK, Ganesh S, Sandhir R.

CNS Neurol Disord Drug Targets. 2019;18(3):172-184. doi: 10.2174/1871527317666181114163515.

Aberrant Neuronal Cell Cycle Re-Entry: The Pathological Confluence of Alzheimer's Disease and Brain Insulin Resistance, and Its Relation to Cancer

Koseoglu MM, Norambuena A, Sharlow ER, Lazo JS, Bloom GS.

J Alzheimers Dis. 2019;67(1):1-11. doi: 10.3233/JAD-180874.

Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications

Khoury R, Grossberg GT.

CNS Drugs. 2019 Jan;33(1):17-29. doi: 10.1007/s40263-018-0590-9.

The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology

Maletínská L, Popelová A, Železná B, Bencze M, Kuneš J.

J Endocrinol. 2019 Feb 1;240(2):R47-R72. doi: 10.1530/JOE-18-0532.

Ethical Issues in the Treatment of Late-Stage Alzheimer's Disease

Watt AD, Jenkins NL, McColl G, Collins S, Desmond PM.

J Alzheimers Dis. 2019;68(4):1311-1316. doi: 10.3233/JAD-180865.

Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)

Wang N, Qiu P, Cui W, Yan X, Zhang B, He S.

Curr Med Chem. 2019;26(30):5684-5710. doi: 10.2174/0929867326666181203124102.

AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development

Novak P, Zilka N, Zilkova M, Kovacech B, Skrabana R, Ondrus M, Fialova L, Kontsekova E, Otto M, Novak M.

J Prev Alzheimers Dis. 2019;6(1):63-69. doi: 10.14283/jpad.2018.45.

Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer's Disease

Chen D, Zhou XZ, Lee TH.

Recent Pat Anticancer Drug Discov. 2019;14(2):144-157. doi: 10.2174/1574892814666181218170257.

Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach

Dhas NL, Kudarha RR, Mehta TA.

Crit Rev Ther Drug Carrier Syst. 2019;36(5):373-447. doi: 10.1615/CritRevTherDrugCarrierSyst.2018026762.

Evaluating the Role of Microglial Cells in Clearance of Aβ from Alzheimer's Brain

Manchikalapudi AL, Chilakala RR, Kalia K, Sunkaria A.

ACS Chem Neurosci. 2019 Mar 20;10(3):1149-1156. doi: 10.1021/acschemneuro.8b00627. Epub 2019 Jan 23.

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

Panza F, Lozupone M, Logroscino G, Imbimbo BP.

Nat Rev Neurol. 2019 Feb;15(2):73-88. doi: 10.1038/s41582-018-0116-6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias